WallStSmart

Enanta Pharmaceuticals Inc (ENTA)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enanta Pharmaceuticals Inc generates 8695% more annual revenue ($65.26M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -96.9%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ENTA

Avoid

21

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 3/9Altman Z: -1.83

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENTAUndervalued (+36.6%)

Margin of Safety

+36.6%

Fair Value

$22.49

Current Price

$12.96

$9.53 discount

UndervaluedFair: $22.49Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENTA0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ENTA4 concerns · Avg: 2.5/10
Market CapQuality
$388.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-53.2%2/10

ROE of -53.2% — below average capital efficiency

Revenue GrowthGrowth
-21.6%2/10

Revenue declined 21.6%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENTA

ENTA has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ENTA

The primary concerns for ENTA are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

ENTA profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ENTA is growing revenue faster at -21.6% — sustainability is the question.

ENTA generates stronger free cash flow (-10M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 21/100). ENTA offers better value entry with a 36.6% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enanta Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?